Form 4: Ionis Pharmaceuticals Executive Reports Stock Transaction
Insider Transaction (Form 4)
C Frank Bennett, EVP, Chief Scientific Officer of Ionis Pharmaceuticals Inc, reported a transaction in 110 shares of common stock on August 31, 2026.
Summary
- Other acquisition/disposition: acquired 110 Common Stock at $51.31 ($5,644) on August 31, 2026; holds 60,128 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
C Frank Bennett — Officer (EVP, Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Other acquisition/disposition | Common Stock | 110 | $51 | $5.6K | 60,128 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Other acquisition/disposition (110 shares) |
Keywords
insider transaction, Form 4, IONS, IONIS PHARMACEUTICALS INC, neutral, C Frank Bennett
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.